Weight-Loss Drug Trial Results 6/5/24

5 Jun 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

CNBC's "Fast Money" Episode Summary: Weight-Loss Drug Trial Results 6/5/24

Podcast Title: CNBC's "Fast Money" Episode Title: Weight-Loss Drug Trial Results 6/5/24 Air Date: June 5, 2024 Host: Melissa Lee Roundtable Traders: Tim Seymour, Steve Grasso, Guy Adami, Carter Wirth Podcast URL: [Fast Money](http://fastmoney.cnbc.com)

---

Episode Overview

In this episode of "Fast Money," the panel discusses significant market movers including NVIDIA's unprecedented growth, Dollar Tree's restructuring, Lululemon's earnings report, and developments in the weight-loss drug sector. The episode features a blend of market analysis, stock evaluations, and discussions on consumer trends.

---

Key Topics Discussed

  1. NVIDIA's Market Surge
  2. NVIDIA has surpassed Apple, becoming the second-largest company by market capitalization with a value surpassing $3 trillion.
  3. Market Commentary:
  4. The stock is up over 11% this week, raising questions about sustainability.
  5. Concerns raised about NVIDIA's high valuation metrics (e.g., 19x revenue).
  6. Panel Insights:
  7. Guy Adami expresses skepticism about the ability to continue at this growth trajectory.
  8. The potential market impact of NVIDIA's stock split and its implications for passive investment flows.
  1. Dollar Tree's Strategic Moves
  2. Dollar Tree plans to sell its Family Dollar division amid decreasing sales figures.
  3. Market Reaction:
  4. The stock dropped as the company faces challenges in maintaining profitability.
  5. Panel Discussion:
  6. There is consensus that the broader discount retail sector is under pressure, with inflation impacting consumer spending.
  1. Lululemon's Earnings Report
  2. Lululemon surpassed earnings expectations and announced a $1 billion stock buyback program.
  3. Key Insights:
  4. Despite strong international sales, North American sales showed stagnation.
  5. Concerns about leadership changes and product lineup were addressed by CEO Calvin McDonald.
  6. Mixed reactions to the stock's immediate surge following earnings.
  1. Weight-Loss Drug Sector
  2. A discussion on Roche's new entry into the weight-loss drug market.
  3. Roche's drug showed promising initial results in clinical trials, matching competitors from Lilly and Novo.
  4. Considerations for Investors:
  5. The importance of long-term viability and safety profiles of new obesity treatments.
  6. Roche's strategic portfolio approach to meet diverse patient needs.
  1. Global Interest Rates and Economic Outlook
  2. Anticipated rate cuts from the European Central Bank (ECB) and implications for the U.S. economy.
  3. Discussion on the interplay between rising debt levels and interest rates.

---

Key Takeaways

  • NVIDIA's Growth: The stock's impressive rise raises questions about valuations and sustainability, with potential market corrections anticipated.
  • Retail Sector Challenges: Companies like Dollar Tree are struggling, prompting significant operational shifts as inflation affects consumer behavior.
  • Healthcare Innovations: The weight-loss drug segment is highly competitive, with Roche's new offerings demonstrating promise but needing thorough evaluation.
  • Market Sentiment: Broader economic indicators, including potential rate cuts and consumer spending trends, will influence market dynamics.

---

Final Thoughts The episode encapsulates the current volatility in the financial market, driven by tech advancements, consumer behavior changes, and the healthcare sector's innovations. The traders emphasize the need for careful analysis and strategic positioning in a rapidly changing environment.

Next Episode Preview: Discussion on Boeing’s recent successful rocket launch and its implications for the company’s future.

---

Disclaimer: The opinions expressed are solely those of the participants and do not reflect CNBC's opinions. The information is provided for informational purposes only and should not be considered as financial advice.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live from the Nasdaq market site in the heart of New York City's Times Square. This is fast money. Here's what's on tap tonight. Climbing the ranks. NVIDIA overtaking Apple to become the second biggest company in the world. It's added over a trillion dollars in market cash in just over three months. Can it keep its spot at the top as the top dog or is there a reckoning coming? We'll debate that. And from dollars to donuts, Dollar Tree looking to prune its family dollar division. What it means for the discount retailer as the stock trades near its lows of the year. Plus, lofty Lulu shares surging after earnings.

0:33Was all the worry overdone? A top roach exact dives into the pharma giant's new entrant in the weight loss drug battle and the return of Traded or Faded, the Chartmaster Edition, how Carter grades the traders' calls. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Steve Grasso, Guy Adami, and Carter Wirth. And we start off with NVIDIA because, I mean, how could we not? The semi-stock that's dominating this market all year long today hit yet another massive milestone. In addition to jumping over 5 % today, Nvidia topped$3 trillion market cap mark for the first time ever, and that move helped it surpass Apple to claim the number two spot in the S &P.

1:12It's not that far away from overtaking Microsoft, who's been at the top consistently since late January. That's a pretty big jump for a stock that was way back at number five on the market cap list at the start of the year. And with a gain of more than 11 % already this week, it might not be long before it jumps even higher. So is there anything that can derail the Nvidia train? And is it just a matter of time before it bumps Microsoft and becomes number one? Guy. It's certainly number one. I mean, we talk about it seemingly every day and justifiably so. And any concern that I've had has been clearly unwarranted, without question.

1:47With that said, the concerns are still there. And it's not in terms of price to earnings, which at 34 times is reasonable given their EPS growth. It's a concern in terms of at 19 times revenue. I mean, historically, this has been a sector that trades at half that type of valuation. Now, if you say to a guy, they're going to be at a$300 billion run rate in the next year and a half or so forth, then we're going to have a different conversation. I just don't think that trajectory in terms of earnings can continue. That's my concern, unwarded as may be. Will this continue? Yeah, because now you have double levered ETFs on the back of NVIDIA.

2:20I mean, the money flow is there. What will stop it? I think when margins start to wane is when people get really concerned. I was going to say, but Guy, there hasn't been a cycle like this ever historically. So how can we compare it to historic PEs or valuations? So you have the stock split coming up. That's obviously a tailwind to it. But let's talk about the passive investment flow. So if you look at the XLK, Microsoft is number one waiting, and they're at 22.5%. Then it's Apple. Then it's NVIDIA. So Jones has been on this, Bank of America. If they surpass Apple, they have to flip. So that means the weightings flip.

3:00So just think about, now I know it doesn't sound like a lot for NVIDIA. It's a$20 to$25 billion event. If that happens, it's not a one-day event. It's a every time someone buys the XLK, it has to be mirrored into whatever the market cap is. I think it's a little extenuated because the stock split. But doesn't that seem like something you do as a pull the fire alarm, last ditch effort? So maybe they're trying to scale out of something that possibly, possibly. No, Tim, I don't mean that it's over. Right. Because I've been I've been bullish on the video since the beginning. But what I think is maybe we're coming to the end of those incredible beats.

3:41$1 ,200 stock going through a 10 for one stocks, but not an$80. Yeah. And it's it's not again, it's not it doesn't have anything to do with being in the Dow. doesn't have anything to do. Like reverse stocks, splits are often very, I would think, very contrived. When you have a story here that also just out of this Computech, I mean, we've gotten drivers over the last couple of days that have had the analyst community to upgrade on top of already extraordinary valuations. And if you think about the$1 ,200 stock, it's even more extraordinary. Think of all the different periods where we've had these outsized moves in NVIDIA, and you can make an argument of all of them, we're in the greatest one of them all.

4:17I mean, I mean, this was a$750 stock on April 19th. It's up 60 % since April 19th. And the thing that's very interesting for the markets here is that the semiconductors as a group, it wasn't just NVIDIA. Now, I realize there's a dynamic here across the board that at least for the AI spend. But, you know, the move in Taiwan Semi was even more impressive today. And they are a close second in terms of the most important semiconductor company in the world, in my view. And the reliance that the world has on Taiwan Semi. and yeah, there's politics and there's a whole lot of other things to worry about.

4:49But the other side of all of this is the Nasdaq, with all the exposure here, does not make new highs against the S &P. So NVIDIA is now 6.6 % of the S &P, Microsoft 7, 6.4. You're reading all this. These are all numbers you're going to read in the papers tomorrow. You're hearing about them now in terms of the weightings and the size of this company. But the Nasdaq has not really done a whole lot. And that's something that I think folks are looking at the market and wondering, you know, hey, that kind of leadership has been very, very tied to semis, which I'd like to believe I've said for a long time, have been the leader of this market.

5:20And they continue to go higher. But the lack of new highs in the Nasdaq, is that a reason to not be long NVIDIA? Or is that even more reason to be long NVIDIA? It's a reason to be concerned about the broader market, especially when you consider that NVIDIA is up 147 percent this year and the Nasdaq is, you know, not even really totally kept pace with the S &P. For right now, let's just boil it down to NVIDIA. I'm in NVIDIA. Should I be worried about the broader NASDAQ? Or should I say, should I make the assumption that NVIDIA is a little bit more immune to what might happen in the tech cycle when it comes to a pullback in enterprise tech spend?

5:53Because that is more defensive spending. Companies will have to spend on AI, the cutback on other things, as we've seen from the likes of CRM and some of the SaaS names. I think that's fair. I mean, Steve's point about passive investing, we've talked about that for years. I mean, money flows in regardless, and I think that will continue. I don't know. I'd like to think I would understand what's going to derail it. I mean, China, Taiwan's been out there forever. That seemingly is not talked about, although, you know, more and more people seem to be coming around to that sort of framework of thinking that that's the potential existential risk.

6:22But short of that, until valuation catches up, it's all systems go. In March, NVIDIA was a$943 stock. It traded down to$750. So it's not immune. People use it as a cash machine. When people think the market's going down, they sell their biggest buffalo in their portfolio. NVIDIA's got to be one of the biggest things that people have had the gains in. That's going to be the first one to be sold. Well, I'll just say this. One of the hardest things to do in markets is probably short stocks. But one of the second hardest things to do is let your winners run. And when you've had a stock like this, I'm sure there's a lot of people out there that are frustrated that they just haven't let this thing run.

7:00And if you've again, all the different periods we've had, we've had five straight quarters now where they've continued to defy gravity. We've had five straight quarters where they've seemingly upped the ante in terms of the growth cycle. And, yes, this most recent event, when we talk about Vera and Rubin and fascinating names for chips, by the way, I mean, women scientists, of course. OK, why are we not surprised, Tim? I'm about to get canceled. All right. I understand. And those are great names. But I think the fact is what the conversation we had yesterday was, OK, when is this? When are we pricing out right now?

7:33We're just worried about Blackwell or we're not even Blackwell's just starting to get on the radar. But the the the ability they're able to sketch in terms of the addressable market. And it does. I am most fascinated for the broader market about this industrial complex and where, again, NVIDIA is talking about where they expect they are going to change physical dynamic industries. And that is something that I think for this multiple is not necessarily in the price. I mean, remember we had we've had the arc futurist on talking about a great name, by the way. Don't you want to be a futurist? I think I mean, I mean, you're wrong.

8:07Futurist. That's a great name. Deer. Deer as an A.I. play. Every sector. That's the next leg. Every sector is going to benefit from A.I. I get it. I also said that 1350 at NVIDIA. When it was still trading below$1 ,000, it was probably still cheap to some people. Now, was it Bank of America just upped it to$1 ,500? So every sector is going to change, but not every sector is going to change the same way. There's not going to be the same chip types. All right, so let's go to the chart master, because we've got a lot of chart questions when it comes to NVIDIA. Obviously, where the stock is going, and also whether the strength relative to the NASDAQ, is that troubling for NVIDIA?

8:46It's obviously troubling for the NASDAQ, Carter, but what's your take? Sure. Well, before we get to the charts, I think we can all be kidding. It turns out no one has a clue about this stock. It's been so exceptional. Just to make it very clear, one year ago, it was trading at$375 in early June a year ago. And Wall Street had a price target of$462, believing it would go up 23%. Well, here we are, and it's$1 ,224, not$462. It turns out it's just one of these things that's exceptional and very hard to handicap how far it will go, when it will end. But we can look at the charts and try to figure out at least maybe the next hour or two.

9:23So let's do that. The formation, the setup, the event that has occurred is that breakout, news related. And now the stock is up some 25%, 30%, having moved from the high 900s to 1225. Let's keep that and then look at this same on a longer term chart. And let's keep that formation and look at it again on a longer term chart, a third iteration. And so the question is, is there any way to tell if this breakout has run its course? Now, final chart, this same time frame, and let's put the channel on. And so simply, were we to get to the top of the channel, you're talking about 1 ,400. Now, I have no clue whether it's going to go there, but momentum like this is dangerous in terms of doubting it or fighting it or certainly shorting it.

10:11It happens to be an exceptional moment for an exceptional stock that will, of course, one day have its reckoning. But right now, the buyers are in the ascendancy. The money is moving in. So it's dangerous, Carter, in your hunch is that it goes to$1 ,400? I would say, I mean, I would be, if you had to press and say, you must be shorter, you must be long this stock for tomorrow at 930 and the next day at 930, I certainly wouldn't be short. So it's either stand aside and marvel at it or participate and be long. All right. Well, as the market cap continues to soar, so does the options volume. Mike Coe joins us for a look at how the traders are playing the world's latest$3 trillion company.

10:51Mike, what do you see? Yeah, I mean, this thing overtook Tesla. You'll remember, Tesla was always the busiest single stock option. That has changed. It became NVIDIA a little while ago. And that hasn't, you know, it's just actually the volume continues to build. And it's important to remember, too, that as the volume builds and the price increases, the notional value of these options positions are also getting bigger and bigger. It traded over 2 million contracts today. Four of the top five most active contracts were calls. Actually, the top four were all calls, all expiring at the end of this week.

11:25And it's interesting that Carter was saying, you know, forget about what it does three months from now. What are we worried about it doing tomorrow, the day after, and the day after? And they're trading mostly weekly options, and they're all trading upside calls. So the 1200s, 1220s, 1215s, 1250s, and the 1300s for this week were the most active contracts. And basically saying, look, I mean, if you're going to play this thing, ride the momentum. So, Mike, you mentioned activity to the end of this week. And, of course, the end of this week captures the stock split. What does it look like beyond this week in terms of the bets?

11:59And is there any sort of inkling that people think this rally will cool off when the stock actually splits? Well, I mean, there was over 800 ,000 puts that traded. So there are some people who are betting against it. But the number of people who are betting to the upside outnumbers them by about 50 percent. So there was one and a quarter million call contracts purchased. And you bring up an important point. For those people who are trading options, what's going to happen to those? And I think there are people who believe that a split is a positive. Each contract will become 10 contracts and the strikes will get divided by 10.

12:35And, you know, so there will actually in the short term be an even larger spike in options volumes in strict contract terms. Although what we have seen in the past is that when those splits took place, more people started migrating back to the stock because they were able to. That's very interesting. Mike, thank you. Mike Coe. So Carter put out two possibilities that he thought you should entertain, and that is stand back and marvel or belong. What's your answer, Steve? I've been standing back and marveling. I'm going to wait until the split and see if I want to jump back in. Stand back and marvel or be long?

13:11Well, at this point, I have to be one of the marvelous marvelers because, you know, getting long here for me would be, you know, just throwing in a towel, which I'm unwilling to do. And Tim? Stay long. I mean, I just don't know why you're fighting stuff that I'm sure it's going to pull back. But, again, it depends on how you invest, what's your time horizon. You're not timing this thing. And, again, letting your winners run. Yeah. What a rip. Now let's get to Lululemon soaring after reporting better than expected earnings and revenue. The company also announcing a$1 billion stock buyback program.

13:41The athletic clothing company has beaten on EPS 20 of the past 21 quarters. CNBC.com's Gabrielle Von Rouge covering all the action joins us now to break down these results. It wasn't just a beat, Gabby. They also raised their guidance for the full year. They reaffirmed their guidance for the full year. But they actually, their Q2 guidance came in lower than expected. So this uptick in the stock, I mean, I'm attributing that to the buyback. That's obviously going to be great for investors. And then also the international growth. You know, this feels a little bit like window dressing, right? You've got the buyback and you have Calvin McDonald on the call talking all about international.

14:14They had sales up 35 percent in the region. China was up 45 percent. Rest of the world was up 27. But what people, what investors need to keep in mind here is that North America was flat during the quarter. That's its biggest market. So those are volatile regions to bank on. So you don't buy this 12 % pop. And have they addressed at all the chief product officer leaving and what happens after that with their lineup? They did. They did address that. And, you know, of course, when that was announced, you saw the stock drop. Investors were really concerned about what kind of impact that's going to have on Lulu's product lineup going forward.

14:46Calvin McDonald did speak about how they had their succession plan in place. They had somebody ready to go. He's going to be reporting directly to Calvin now. They're not going to actually replace the position, but they have reassured investors that this isn't going to cause an issue. Gabriel, great having you on set. And, you know, a guy who's a fashion plate and is often a leading indicator of fashion said nine to 12 months ago, watch out for skinny leg jeans and denim's coming back. I'm actually I'm going into flares. Wide leg, Tim. Low rise, wide leg. Whatever. Tim's going into flares. So why?

15:16Belly button showing. Why is this really an issue? I mean, don't all of these companies adjust and adapt? And as much as I recognize competitive landscape, I think they are losing market share. I do think there's saturation. Why do we continue to hear about this? You know, that's what investors have to keep in mind. Fashion is fickle and it's cyclical. These things are always going to change. Think back to the 2000s when true religion was one of the hottest brands on the market, right? You had celebrities wearing the wildest jeans. And you know what killed denim? Athleisure. And now denim is back with a vengeance.

15:47And Lululemon is never going to sell jeans. It is an athletic apparel company. So there's no really room for them there. You had true religions. I bet you any and I have money. So my response to that is who didn't? First of all, I didn't. Second of all, it's great having you here. And I'm sorry you have to endure the low ride. Did you even say that? You're thinking of stripes. I mean, who knows the right terms. You're on it. Flares, right? But are you skeptical of this pop in the afters? Yeah, I am. I'll tell you. Well, listen, this is the good news. Inventories were down almost 15 % year over year against sales growth of a 10.5%.

16:22Very good. and margins were they beat, but still down year over year. All very good things. But as Gabrielle said, America was flat. I mean, that's still the big kahuna there. And the second quarter guide wasn't great. They're trying to get you to believe the full year guidance is going to come in better than the street was expecting. So the billion dollar stock buyback doesn't do a whole lot for me. I think it's a relief rally. I thought we'd trade down to the June 22 lows of 275. We didn't get there. But I think you fade this move. Yeah, I take it as if the puck's going to denim, then you've got to buy Levi's.

16:52And Levi's chart actually looks really good. It's up 46 % year-to-date. And not only is there denim, get a Q-tip, there's stretch denim, right? So that's the next leg. It's not just regular denim now. And it's not the stretch. Huh. It's not the yoga pant denim. It's a real jean. Is that sport coat you're wearing, stretch denim? It should be. It should be. It should be. So I think that that chart's good. And if you get another one, Ralph Lauren, that chart looks good as well. Yeah. Abercrombie & Fitch, American Eagle, Gap, they're all well positioned to capture this denim trend. And it's also not just about the wide leg and the low rise.

17:31It's a head-to-doe denim outfit. Oh, head-to-toe. You had Caitlin Clark wearing a full denim jumpsuit, totally on trend. But it's denim jumpsuits, it's denim jackets, denim shirts, Levi's. Denim jumpsuits? Yes. And put in country music and it all fits together. I got it. I've got to get moving here. Tim's going to go to shopping this weekend. We can go shopping. I'll show you what to do. Thank you. I'm going to need some help. Thank you. Coming up, Europe may be getting ahead of the U.S. The ECB nearing its first rate cut since 2019. While yields here at home continue to drop. What the front running could mean for global markets next.

18:06Plus, branching off, Dollar Tree dropping as the company looks to sell off its struggling family dollar business. How that move could impact the stock when Fast Money returns. This is Fast Money with Melissa Lee, right here on CNBC.

18:28Welcome back to Fast Money, a key interest rate decision coming tomorrow. The ECB expected to deliver its first rate cut since before the pandemic, that after the Bank of Canada cut its rate by 25 basis points today, its first move in four years. Meantime, more softness in U.S. Treasury yields with the Federal Reserve's policy decision one week away, the 10-year at its lowest level in more than two months. So what does this all mean? Let's get some answers from CNBC on-air editor Rick Santelli. Rick, last time you were here, maybe not the last time, but the last time when you set the internet on fire with your prediction for the 10-year yield, you said that rates would go, I think it was like north of 15 percent.

19:07That was the prediction? I think it was 10. Ten? Fourth of ten. Whatever it was, wildly higher from where they are now. You throw in the towel on that? Yes, double digits. Double digits, yeah. Double digits. And I said it was a possibility, and I still certainly believe that, and I'll tell you why. It's an election year, and what's going to happen in this election year? Tax policy, tax cuts, implement, remove them, how that affects deficits, static versus dynamic scoring. We're going to galvanize the public to all the issues that interest rates are definitely going to be held hostage to. And in my opinion, tomorrow, there's not going to be any surprises with the ECB.

19:47They can't afford it. The engine of Europe, Germany, is sputtering. Why? They can't even afford the energy costs of the industrial base. Their energy price keep going up and hold that thought. It's not going to be much different here. So in my opinion, I could see a test of under 4 % with this move. We have five consecutive days where the 10-year has had a lower low than the previous day. We've had five consecutive lower yield closes. It is building momentum, all because of the Fed. But the reality is, is that every week or every other week when we have big coupon auctions, we redirect investor focus, and interest rates go up.

20:25We redirect them more towards the Fed and central banks. Interest rates go down. I'll tell you what's important. Here's what's important. The federal interest payments are now, boom, approaching$1 trillion. And, as I said, if the Democrats win, it's going to be get rid of the tax cuts. They'll use static models. But that doesn't make any sense. Why? Here's federal revenue starting in 1980,$517 billion. Then we popped over$1 trillion in 1990. 2000, we popped over$2 trillion. And the tax cuts happened, what, in 2017? In 2015, we had$3.25 trillion of income. In 2020,$3.42 trillion. In the last year,$4.44 trillion.

21:08Does that look like we have a taxing problem? We have a spending problem. And we can all have pretty talking, blah, blah, blah, about central banks. But I will tell you this. Look at the spread between tens and boons. Today, it's hovering around$175 trillion. It's the tightest it's been in four months. How do you think that's going to react tomorrow? What does that underscore? It underscores the U.S. is going to have to pay up to borrow, and that's going to end up raising the price of poker for all the countries, China, the Eurozone, the U.K., as they all have to come to the well because their economies are not going to look as good next year as they did last year.

21:47Rick, I show your concerns. Jamie Dimon has said similar stuff. So I'm with you. You have these conflicting forces without question. But what's sort of the cat like debt to GDP is approaching 130 percent. That seems to be the line in the sand. No developed economy seemingly can recover from that. You know, what are your thoughts when this part of the equation, the supply side becomes more important than the slowing growth side? Well, that's where you have your possibility of double-digit interest rates. I think if that makes one feel uncomfortable or it feels too crazy to be true, then look for steepeners.

22:23You know what's going on right now? We're getting more inverted as we rally. We're hovering, what, around 45 basis points minus 45 in twos to tens. We had periods where it was in the low 30s, even looking like it was going to go into high 20s. But it backed away. I really do think that we have a two-speed interest rate scenario. We have one where it's going to be central banks and they're going to be pressuring the short end. But the rest of the long, mid to long end is going to be focused on supply and all the issues of politicking as we get closer and closer to the election. And in my opinion, inflation is that third stool.

23:02OK, here's what we have in third leg on the stool. Growth. Growth is definitely slowing, guys. Employment, labor definitely seems to be slowing, and its continuing claims don't point to it. But there's many other better metrics, whether it's quits or job openings. All those issues are definitely moderating. The one thing that I don't think is moderating enough is inflation. The Fed will find a metric it likes, whether it's a PCE, whether it's a deflator, whether it's X Energy. But I'll tell you what, you don't need to be a rocket scientist to figure out how many trucks are on the road when you drive.

Read the full transcript

23:34A lot of them. How much does diesel fuel cost today? How much does an electric truck cost in California? I'm telling you that everything we buy is going up and energy is going to be at the bottom of that. And the Fed, they could raise rates to 30 percent. It's not going to stop that dynamic. Rick, always good to see you. Thank you. Thank you. Rick Santelli. Carter, we know where you stand on rates. Do you think the rates are going lower? Is that right? Yeah, you know, happily. Right. All of that is so compelling, you know, and but happily, I'm not in the why business. I'm in the what business.

24:09Right. And what's happening now is that rates are are sinking lower and lower. And almost two years later, they're not higher for longer, et cetera, and so forth. So for now, yeah, I'm in the lower rates camp. All right. There is a lot more fast money to come. Here's what's coming up next. The apple doesn't fall far from the tree, but family dollar may. why Dollar Tree is looking to sell off one struggling unit and what it'll mean for the discount retailer. Plus, competition sizing up in the weight loss drug space. The latest developments from one healthcare company looking to tip the scales in their favor.

24:46You're watching Fast Money, live from the NASDAQ market site in Times Square. We're back right after this.

24:57Welcome back to Fast Money. Shares of Dollar Tree taking a hit today. The company announcing it may look to sell its struggling family dollar business, which it bought back in 2015. As consumers continue to struggle with high inflation, back in March, the company announced it would close nearly 1 ,000 family dollar stores. So maybe not entirely a surprise. Was the stock reaction a surprise, Guy? I don't think so, because this trajectory has been going on for quite some time. I mean, basically upper left, lower right. And if you put up a chart, you'll see what I'm saying. And it's not just Dollar Tree.

25:27I mean, dollar gen is similar. We're going to look at five below if you want to throw a chart up in the after hours. You see what's going on there. I mean, there's clearly problems on that end of the spectrum, which, again, speaks to the health or lack there over the consumer. So no, it doesn't surprise me. And I do think it has more to go on the downside. Five below now down 14 percent on earnings. Yeah, look, I think there is more pain to come here. But I think there were some some parts about this quarter that I think are overlooked. Look, first of all, I mean, their SG &A increase was offset by gross margin also increasing.

26:00And so on some level, you've actually seen a little bit of relief in here. These are tough times. And, you know, the Dollar Tree, which, you know, can't charge anything. It can't really you can't buy anything for a dollar in there anymore. So, I mean, it is a dynamic where I think this segment has really been suffering. And I also think that Walmart continues to take lunch on both sides of the spectrum from the lower tier and from the upper tier. and it's Walmart's game. Five below's chart looks the worst. It's down 37, 38 percent year to date. Actually, more given given what's going on in the post market.

26:31But dollar gen, they look the best on this and they look the best in the worst world or the worst segment. They're only down one percent year to date. Dollar Tree had issues before the takeover. They have issues during and they have issues after. And they're closing stores. I think that if you want to invest here, You have to wait until inflation gets under control. What do you see in the charts, Carter, for a Dollar Tree or a Five Below? Yeah, you know, it's funny. Just something I was just looking at when you all were talking. You know, we think of every dog has its day. Just consider this. Since its IPO in 1995, Dollar Tree is up 5x over Walmart.

27:10Now, think about that. What? Dollar Tree? This dud? This loser who's having to sell off a division that it bought? it's up 5x over Walmart from 1995 to present. And so the question is, it's not about a good company or a bad company by which there are moments when things are good, NVIDIA, and there are moments when they're bad, Walgreens boots. Right now, Dollar Tree's on the ropes. I wouldn't want to own this stock here. But just to put it in context, its history is it's crushed Walmart, the greatest retailer of all time, with the exception of any Amazon. on. Coming up, shares of Roach Holdings getting a pop over the last month as its entrant in the weight loss drug space gained some traction.

27:50A top exec will join us to lay out the GLT-1 pipeline. That's next. And finally, some good news for Boeing. The company launching its Starliner rocket this month, this morning, excuse me, with astronauts on board for the first time ever. But can the successful launch help send shares into orbit? We'll debate that when Fast Money returns.

28:10I'm on the go. Follow the Fast Money podcast. We're back right after this.

28:21Welcome back to Fast Money. The S &P 500 and Nasdaq closing at fresh record highs as NVIDIA surge continues. The Dow also climbing nearly 100 points. Disney doubling down in Florida after settling the Ron DeSantis legal feud. The media giant set to invest up to$17 billion in its properties there with a potential fifth theme park in the state. And a couple more after hours movers for you. Victoria's Secret posting an earnings beat and revenues in line with estimates and ChargePoint. ChargePoint is posting light Q2 revenue guidance. That stock is down just a half percent right now. Meantime, Roach Holding holding onto the gains it made after releasing early stage data on its injectable obesity drug.

28:57Last month, the treatment helping patients lose an average 18.8 percent of their body weight over 24 weeks, giving the drug a potential edge in the highly competitive field. It's one of three GLP One candidates Roach acquired from Karmic Therapeutics back in December. Joining us for more on the GLP pipeline is Dr. Manu Chakravarti, Roach's Senior Vice President, Global Head of Cardiovascular Disease. Manu, great to have you with us. Thank you for having me. Good to be here. The analysts were very excited about the outcome because it really stacked up to Lily's and Novo's product at the same point in terms of 24 weeks in.

29:33What can you tell us in terms of, you know, let's say everything's a go, how quickly could you potentially get this drug to market? Yeah, I mean, so look, we were really excited about this data, right? I mean, as you pointed out, 19 % in six months, roughly, translating to that's about 40 pounds or so in six months. That's really exciting. That's the type of weight loss that really can be, you know, moving the trajectory of health, right? Over 20 % of weight loss typically results in, you know, massive improvements in cardiovascular health, diabetes remission, protection of the kidney, et cetera.

30:07So I think we're all very excited about the fact that this is a very meaningful data set. And so we're going to do everything we can to move this as quickly as possible. But we also know that this is a long road, right? I mean, this is drug development. There's lots of journeys here, lots of milestones. So this is one of the critical milestones that we want to have. You know, at Roche, look, we're taking a little bit of a longer term view, and we're really focused on providing a data package that is as competitive as possible. You pointed out that, you know, it is a very competitive field. So the focus is really to provide as wide an access to as many people who need these medicines as possible.

30:48We didn't get too much in terms of the adverse side effects associated with this trial. and that's what analysts are sort of looking for, although we do understand that it's comparable effectively. I'm wondering also if you see comparability in terms of the muscle loss associated with using these dual agnists, similar to Lillian Novo's product. Yeah, so I think with the 20 percent weight loss, you know, I think it should be anticipated that, you know, there will be some degree of lean mass loss. So we haven't yet measured that in this particular study, but we will be collecting that data in upcoming studies, no doubt.

31:24You know, having said that, I would say that we're well aware of that as a critical side effect, you know, besides the GI tolerability that you indicated. So that is another reason why, you know, we take a little bit more of a longer term portfolio centric approach and really start thinking about CT388 not just as an agent in and of itself, but we also have others in our portfolio that we can combine to really think about not just the magnitude of the weight loss, but can we actually get to better quality of the weight loss, meaning preservation of the lean mass, improvement of muscle function.

31:57And most importantly, I think what patients really need is the weight maintenance or the durability of the response. Are any of the products in the pipeline so far, are you thinking of them as potential weight maintenance solutions? We just heard from Structured Therapeutics, and a lot of people believe that their offering could be used as a maintenance solution. I know you've got CT996, which is an oral agonist, and I'm wondering if that is a replacement for an injectable, in your view, or if it could potentially be a weight maintenance product. Yeah, so I'm glad you asked that question because, you know, the way to think about obesity is that, look, this is not a disease that is a one-size-fits-all, right?

32:40It's very heterogeneous. So I think we need to, as healthcare providers and drug developers, obligate it in some ways to meet the patients where they are in their weight management journey. So we really, again, to reiterate a portfolio-centric view, there are people who will need the injectables, and CT388 is certainly a great representation of that. But we also believe that in order to really meet patients where they are, we would need oral therapeutics too, and CT996 is one of those. So we look at it as not only where we can use them as patient segments matter, but also potentially as weight maintenance therapy.

33:18So after a weight loss induction period, for example, we can very much envision using CT996 as a weight maintenance therapy. Much easier to take pills for a majority of people than injecting every week. The phase one data for CT996 is due out at the end of June or beginning of July. How does it look so far? We'll have to wait and see. I haven't seen the data, obviously. But it is anticipated very much with equal excitement, I would say. Some of the preliminary data that we had put out when the drug was still with CARMOT indicated that this is a drug that certainly has the potential to be clearly once daily based on the PK profile.

34:04And it certainly has the potential to be, you know, I would say as good, if not, you know, as better in some ways for other molecules in space. All right. Dr. Chakravarti, thank you so much for joining us. We appreciate it. Thank you so much for having me. All right. So it's not necessarily Lilianovo's entire market to have. Or maybe it is. So those are the key players. There's an Amgen. Amgen is probably a third player. So people are always looking for who's the one that nobody found yet. So they'll probably get some money out of this. But I think you're better off buying XBI and looking for micro cap that's going to be taken out.

34:43What I heard from this news is that Roche has a lot of room in their CapEx and R &D budgets to continue to try to develop GLP assets that they think have an opportunity. It does lead to more competition right now. It doesn't seem like the competition is there. Yeah. Stock quickly sold up 40 percent over the last year, but it got down to levels we saw three or four years ago. Twenty eight held. And, you know, they have a growth problem. But the valuation suggests you could take a shot here, despite the fact Goldman just initiated with a sell rating, which I thought was interesting. But I think you buy Roche.

35:13The R and granolas. Excuse me. The R and granola. The R and granolas. What is that? What is that? Yeah. Granolas. It's the European acro. I mean, come on, man. It's like these are the exciting kind of growthy, you know, version of European big cap. So it has like two R's and three L's. Well, they're playing it wrong too. Yep. Coming up, Boeing to the moon, sort of. What today's successful Starliner launch means for the company's turnaround efforts here on Earth. That debate is next. And CNBC is celebrating Pride Month throughout June. Here's the chief marketing and solutions officer at SAP.

35:47As a mother of a non-binary child, a proud mother, I want my child, I want all of my friends, my colleagues in that community to be able to be given every opportunity that they deserve without facing hate, without facing bias. So that's why I choose to become an ally, because I have the power to reach out to new communities. I have the power to change minds. And so I want to use it for good.

36:17Welcome back to Fast Money. Finally, some good news for Boeing, the company launching its first crewed Starliner flight this morning. Bound for the International Space Station, today's successful launch comes after several delays and aborted attempts dating back to last summer. The most recent coming this past Saturday. Is this a sign that Boeing can get its terrestrial operations up off the mat? Alright, Tim. So, you're in this. Well, yeah, and I'm trying to think about Boeing, but of course I can hear Green Day in the background when I come around to be on the set. We play cool music here. So, we definitely do.

36:50So, I think about Boeing, and I think about, again, the noise versus the reality of free cash flow. At some point, we are going to see free cash flow eaten into. And in fact, that's really what I think as you look into early 25, not only is there not free cash flow flowing, but there's actually burn. This is the whole story for me around Boeing. I think the whole story has now obviously been pushed out, but I think not by as much as you would think, given the news flow. I think this is a company that's going to have, you know, 15 bucks of free cash flow per share out by 26. And that's the reason I stay in the stock, because I don't bet against a company that I understand the news flow has been awful.

37:28Guy brings it up all the time. It's not just about their commercial airplane business. It's about a defense business and it's about a duopoly. Carter, what's your take on the chart here? Yeah, I mean, this kind of goes in the pair of twos category, which is to say no discernible immediate opportunity, at least to my eye, on the long or short side. But conceptually, theoretically, I'm with Tim. I mean, at some point, it is Boeing. Hard to use that as a timing tool or a valuation tool or an investment tool. But it is Boeing. And at some point, they'll have to right the ship. All right. Coming up, America's favorite game is back.

38:04Traded or faded, but with a twist. What the chart master thinks about some of this year's high flyers. That is next. More Fast Money in two.

38:18Welcome back to Fast Money. Big tech driving the market higher this year. But there are some other high-flying names that caught our attention. So it's time to bring back America's favorite game with the Chartmasters technical twist. Is this really America's favorite game? Why are you questioning that? That is a premise. I mean, that's just a given. We're very truthful here. No, no, no, no. All right. We start off with first. It's up 42 % in just the past month. Steve, trade it or fade it? So I would fade it, but this was Carter and my chart of the month last week. So I do believe that you have a future in this name.

38:53But when you see it spike up the way it has right now, we're back to 2008 levels thereabouts. UBS is a big bull on the name. I would say fade it, let it come back in, reassess. Carter? Well, right. A textbook breakout. Let's look at a chart and sort of try to figure out whether what Steve is saying is right. And it is. I mean, it's come a long way. The stock is trading. Look at this. Wall Street's price target for a year ahead is 260. And it's trading at 273. So Wall Street believes you've got 37 analysts covering it that it will be lower in the next 12 months. But either way, a textbook breakout.

39:29And now I've got a sideways there, which is I think it's going to back and fill. I'd sell calls. I do something where it would not sit just blindly long after a 40 percent move in 10 sessions. All right. So he's fading it. Let's get to Kava here, up nearly 30 percent in the past month. Tim, who questions whether or not this was America's favorite game. Do you trade it or fade it? I'll be, I guess, equally cynical on Kava. I just I think that the move this stock has had is exciting. It's obviously a gross story. It's obviously whether this is the next CMG or someone like that. This is what we're getting.

40:05It's what we're getting in fast casual. We're getting the margins. Their margin numbers and their margins in the first quarter were very impressive. Having said that, this is a company that's going to earn 55 cents a share next year in terms of somewhere around consensus. Ninety two dollar stock. You guys can do the math on that. That's a very expensive stock for a ten and a half billion dollar company that I think that, you know, again, the marginal increases from here are a lot harder to achieve. I'm a seller. Trade it. And they may fade it, fade it, fade it, fade it, fade it, fade it, fade it, fade it, fade it, fade it, fade it, fade it.

40:32Yeah. Maybe you don't like it because you know how to play. Whoa. It's not his favorite game. Oh, she's in my grill. I deserve that. You questioned it. I said it's America's favorite game. You said, is it? Well, again. I don't like that. We are strict. Yeah, we don't like that. Carter, what do you say?

40:50Sure. Well, here's another one just for fun. I thought this sort of price target thing is always fascinating when you've got, in this case, from 14 analysts, and they believe the stock is worth$88 in the coming 12 months, trading at 92. do. So here again, Wall Street and its infant wisdom thinks this will be lower than higher. But the chart, it's a pretty orderly, steady uptrend. My hunch is I got a green arrow there is just stay with this momentum. My inclination is to trade it. All right. And let's get to Decker's here. Also, 30 percent in just the last few weeks. So, Guy, do you trade it or fade it?

41:21This is I'll play the game correctly. Fade it, Melissa. I'll start with that. You're welcome. Well done. And I'll say this is one we've actually liked. But the parabolic nature of this move suggests that it's going to stall at some point. The quarter was great. Inventories are under control. Margin expansion. But valuation is a little bit stretched. And, you know, a move basically of four bagger in the last two years suggests it's going to take a breather. How many pairs of Uggs do you have? I have hocus, Tim. I don't have any Uggs, okay? Because when you put your Uggs in the fur and they sweat, they think stink.

41:54Back to you, Mel. Really too much information. Carter, what say you about deckers? Sure. I'm in the faded category again here, too. Wall Street thinks a stock's worth less than a year than it is now. Look at the chart. It is a textbook breakout, but fade and or sell or hedge, do something. All right. Up next, final trade.

42:22Time for the final trade. Carter Braxton Worth. Silver has just dipped 10 % by the SLV. Tim? It may not be America's favorite game, but this is America's favorite show. Santa Fe. Oh. Steve? I think it is America's favorite game. CRISPR. I'm staying with that biotech angle. CRISPR final trade. Guy? I'm looking forward to seeing Tim in his low-rise. Low-rise flares. Shorts and long. That's America's favorite game. Carlisle Group, CG, seems to have found a home here. All right. Thanks for watching Fast. See you back here tomorrow at 5 for more Fast. Meantime, don't go anywhere. Mad Money starts right now.

43:00All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, Internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:34To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed. 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Weight-Loss Drug Trial Results 6/5/24CNBC's "Fast Money" · 44 min
Listen in VO